| Age | 45±16 | 44±14 | 47±17 | 0.33 |
| Male sex, n (%) | 19 (21) | 8 (18) | 11 (24) | 0.61 |
| SLE, n (%) | 25 (27) | 12 (26) | 13 (27) | 1 |
| Load of antibodies, n (%) | | 0.94 |
| 1 | 29 (31) | 15 (33) | 14 (29) |
| 2 | 40 (43) | 19 (41) | 21 (44) |
| 3 | 25 (27) | 12 (26) | 13 (27) |
| Anticardiolipin antibodies, n (%) | 76 (81) | 36 (78) | 40 (83) | 0.60 |
| Antiβ2-GlycoproteinI antibodies, n (%) | 59 (63) | 27 (59) | 32 (67) | 0.52 |
| Lupus anticoagulant, n (%) | 35 (66) | 18 (78) | 17 (57) | 0.14 |
| Family history of thrombosis, n (%) | 17 (31) | 10 (40) | 7 (24) | 0.25 |
| Tobacco use, n (%) | 41 (44) | 21 (46) | 20 (42) | 0.83 |
| Hypertension, n (%) | 45 (48) | 21 (46) | 24 (50) | 0.69 |
| Dyslipidemia, n (%) | 43 (46) | 21 (46) | 22 (46) | 1 |
| Diabetes, n (%) | 4 (4) | 2 (4) | 2 (4) | 1 |
| Antimalarials, n (%) | 34 (36) | 16 (35) | 18 (37) | 0.83 |
| Heparin, n (%) | 34 (36) | 16 (35) | 18 (37) | 0.83 |
| Oral anticoagulants, n (%) | 68 (72) | 33 (72) | 35 (73) | 1 |
| Antiplatelets, n (%) | 71 (76) | 33 (73) | 38 (79) | 0.63 |
| Corticosteroids, n (%) | 5 (5) | 2 (4) | 3 (6) | 1 |
| Immunosuppressants, n (%) | 4 (4) | 1 (2) | 3 (6) | 0.36 |